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The epidemiology of meconium aspiration syndrome (MAS) in term neonates is described in a population-based retrospective
study of data recorded for all births from 2000 to 2007 in a French region (Burgundy). Of the 132 884 eligible term newborns, the
rate of meconium-stained amniotic ﬂuid (MSAF) was 7.93%. The prevalence of severe MAS was 0.067% in the overall population.
MAS rate was 0.11% at 37-38 weeks of gestation (WG), 0.20% at 39–41WG, and 0.49% at 42-43WG. Factors independently
associated with severe MAS were identiﬁed by a case-control study, that is, thick meconium amniotic ﬂuid, fetal tachycardia,
Apgar score ≤3 at 1minute, and birth in a level III facility. Our results conﬁrm the high prevalence of MSAF after 37WG but also
show the low frequency of severe MAS in a period corresponding to the new international recommendations on the management
of birth with MSAF.
1.Introduction
Meconium aspiration syndrome (MAS) is an infrequent
but life-threatening respiratory disease aﬀecting some of
the infants born through meconium-stained amniotic ﬂuid
(MSAF).
MAS may be a severe condition as 30 to 50% of MAS
required mechanical ventilation or continuous positive air-
way pressure (CPAP) [1, 2].
MAS is frequently associated with fetal hypoxia which
promotes meconium discharge in amniotic ﬂuid, gasping
and aspiration of MSAF, and also changes in the vascular
muscular media of pulmonary arteries of the fetus [3, 4].
In the early 2000, the prevalence of MAS ranged from
0.20% to 0.54% in the general population [5–7]a n df r o m
1.0% to 6.8% in infants born through MSAF [3, 5–7]. A
review of ten reports published from 1990 to 1998 showed
a combined incidence of 13.1% for MSAF, 0.52% of MAS,
4.2% of MAS among MSAF, and 49.7% of MAS requiring
ventilatory support with a 4.6% mortality rate [6].
However, large population-based studies were scarce and
suggested a lower incidence of MAS: the national US birth
cohort study conducted on the basis of singleton term non-
Hispanic white live births (1995–2001) showed that the rate
ofMASmarkedlyincreasedwithgestationalage(GA),thatis,
from 0.10% at 37 weeks gestation (WG) to 0.22 and 0.31% at
40 and 41WG, respectively [8]. The prevalence of MAS
could be extrapolated to 0.18% in this population of term
infants. In Australia, the rate of MAS requiring mechanical
ventilation in level III units ranged between 0.024 to 0.046%
at 36–40WG and then increased to 0.080% at 41WG and
0.14% at 42WG [9]. In France, the prevalence of mechan-
ically ventilated MAS was estimated to 0.043% by a retro-
spective national survey among neonates born in 2000-2001
[10].
Previous studies identiﬁed several risk factors of MAS
that is, fetal compromise indicated by abnormalities of fetal
heartratetracingsand/orpoorApgarscore[1,11–16]and/or
low cord pH [5, 17]; Cesarean delivery [1, 18]; ethnicity
(black Americans, Africans, Paciﬁc Islanders); advanced ges-
tation[15,19,20].However,studiesbasedontheglobalpop-
ulation did not speciﬁcally address the determination of risk
factors of severe MAS among infants born through MSAF.
It is worthy to note that regionalization of perinatal care2 International Journal of Pediatrics
concentrated high risk pregnancies in level III facilities, a
condition representing a potential bias in assessing preva-
lence of severe MAS and identiﬁcation of risk factors.
Therefore, a population-based study was designed to
conﬁrm the low prevalence of severe MAS and identify risk
factors of severe MAS among term infants born in MSAF.
2. Methods
The database of the Burgundy perinatal network was studied
for the years 2000–2007. The Burgundy perinatal database is
a voluntary collaboration between all 18 public and private
hospitals in Burgundy (level III: 1; level II: 7; level I: 10) [21,
22]. The database which was set up with the approval of the
National Committee of Informatics and Liberty includes all
mother-infant pairs. Perinatal data are recorded at the time
of neonatal discharge from maternities or neonatal units.
Procedures are established to ensure quality of the recorded
data, including standardized deﬁnitions, guidelines for cod-
ing, and validation of data coherence by speciﬁc softwares
[21, 22].
All live births are eligible if their GA was ≥37 WG’ es-
timated GA. Exclusion criteria included severe congeni-
tal malformations, chromosomal abnormalities, congenital
neuromuscular diseases, and metabolic diseases.
AllcasesofMSAFandMASwereidentiﬁedintheperina-
tal database. Severe MAS (i.e., treated by mechanical ventila-
tion and/or continuous positive airway pressure) and their
controls were conﬁrmed when the medical records were
systematically reviewed and abstracted by an independent
neonatologist assessor (C.R or C.F). The diagnosis of MAS
was established according to diagnostic criteria from Rubal-
telli et al. [23], that is, respiratory distress with elevated oxy-
gen dependence; presence of meconium in amniotic ﬂuid;
chest radiograms with massive bilateral patchy inﬁltrates
with or without pleural ﬂuid. For each patient, the type
MSAF was qualiﬁed as “thin” when the ﬂuid was just tinted
yellowish or slightly greenish, “moderate” when it was really
greenish, but ﬂuid and “thick” when it was green and thick.
The GA, in completed weeks, was assessed on the basis of
the mother’s last menstrual period as conﬁrmed or modi-
ﬁed where necessary by routine early antenatal ultrasound
examination. Owing to the low prevalence of MAS, a case/
controlstudyappearedoptimal.ForeachcaseofsevereMAS,
3 controls born in MSAF without any respiratory distress at
birth were obtained from the regional database. Cases and
controls were paired according to GA assuming a prepon-
derant role of GA in MAS incidence [8, 9, 24–28]. The
recordedvariablesarethoseshowninTable2.Fetalheartrate
recordings were precisely reviewed and classiﬁed according
to French guidelines (fetal tachycardia, bradycardia, deceler-
ations, decreased variability) [29].
2.1. Statistics. Quantitative data were presented as a mean
and standard deviation (SD), and compared by one-way
analysis of variance or, if normality or homoscedasticity as-
sumptions, were violated Mann-Whitney U-test. Qualita-
tive data were presented as percentages and compared using
Pearson Chi Square or, in the case of very rare conditions,
Fisher’s exact test.
Secondly,aconditionallogisticregressionwasusedtode-
termine signiﬁcant independent variables associated with an
increased risk of severe MAS. The model was adjusted for
amniotic ﬂuid, Apgar score ≤3 at 1min, level of birth place,
mode of delivery, insuﬃcient followup during pregnancy,
andtachycardiaorbradycardiaonFHRrecordings.AP value
below0.05,fora2-tailedWaldtest,wasconsideredasstatisti-
cally signiﬁcant. First-order interactions were systematically
tested by a 2-tailed Wald test and excluded from the model
if they did not reach statistical signiﬁcance at the 0.05 level.
Adjusted odds ratio (OR) and their 95% conﬁdence intervals
(CI) were calculated.
Statistical analyses were performed using SAS 9.2 (SAS
Institute Inc) and Stata 8.0 (StataCorp LP) packages.
3. Results
The Burgundy perinatal database collected a total of 133 087
births with GA ≥37 WG from the period beginning January
1st, 2000 and ending on December 31st, 2007. Of these
births 203 had exclusion criteria and 10 540 of the 132 884
eligible neonates (7.93%) were delivered within MSAF (thin,
moderate, or thick).
The incidence of MSAF linearly increased with GA
(Figure 1). The rate of MSAF was 3.52% at 37-38 WG versus
9.07% at 39–41WG (OR = 2.74 [2.56 to 2.92, P<0.0001])
and 14.37% at 42-43WG (OR = 4.60 [4.03 to 5.26; P<
0.001]).
The regional database identiﬁed 241 neonates with MAS.
TheprevalenceofMASwere0.18%oftheoverallpopulation.
The incidence of MAS markedly increased with GA after
39WG (Figure 2). The rates of MAS were 0.11% at 37-38
wks versus 0.20% at 39–41 wks (OR = 1.86 [1.27 to 2.72,
P = 0.0013]) and 0.49% at 42-43 wks (OR = 4.65 [2.34 to
9.27; P<0.0001]).
TheoddsratiosofMSAFandMASateachgestationalage
are indicated in Table 1.
The global prevalence of MAS in neonates born with
MSAF was 2.29% and did not signiﬁcantly change with GA
(Figure 1).
Among the 241 MAS, treatment modalities were oxygen
alone in 152 (63.1%), nasal CPAP without mechanical venti-
lationin3(1.2%),conventional ventilation withouthighfre-
quency oscillation (HFO) in 69 (28.6%), HFO in 17 (7.1%).
Therefore, severe MAS (i.e., MAS treated by mechanical ven-
tilation and/or nasal CPAP) was identiﬁed in 89 neonates.
The prevalence of severe MAS was 0.067% of the overall
population, 0.84% of neonates born through MSAF, and
36.9% of MAS.
Amongst the 89 severe MAS the median of duration of
mechanical ventilation (conventional ventilation and HFO)
was 2.0 days (1.0–5.0). Surfactant was given to 34 and anti-
biotics to 79 of the 89 infants with severe MAS (38.2% and
88.9%, resp.). Nitric oxide inhalation and ECMO were used
in 15 (16.8%) and 2 (2.2%) infants, respectively. The ne-
onatal course was associated with persistent pulmonary hy-
pertension of the neonate in 14 (15.7%), air leaks in 10International Journal of Pediatrics 3
Table 1:Oddsratios(95%CI;P value)ofmeconium-stainedamnioticﬂuid(MSAF)andmeconiumaspirationsyndrome(MAS)inneonates
born between 38 and 43WG compared to neonates born at 37WG.
38WG 39WG 40WG 41WG 42SA 43WG
MSAF 1.11 [0.97, 1.28;
P = 0.13]
1.94 [1.71, 2.20;
P<0.0001]
3.22 [2.84, 3.63;
P<0.0001]
4.08 [3.61, 4.62;
P<0.0001]
4.96 [4.20, 5.87;
P<0.0001]
5.29 [2.03, 13.8;
P = 0.0007]
MAS 0.89 [0.42, 1.90;
P = 0.77]
0.96 [0.48, 1.93;
P = 0.92]
2.10 [1.09, 4.03;
P = 0.026]
2.25 [1.16, 4.38;
P = 0.016]
3.97 [1.65, 9.55;
P = 0.002]
27.3 [3.40, 220;
P = 0.002]
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Figure 1: Rates of meconium-stained amniotic ﬂuid (MSAF) in
the global population and rate of meconium aspiration syndrome
(MAS) amongst MSAF according to gestational age in term and
postterm deliveries.
(11.4%), hypotension in 20 (22.5%), and late-onset neonatal
infection in 4 (4.5%). Concerning thin versus moderate or
thick meconium, mechanical ventilation duration was 1.0
(1.0–4.0) versus 2.0 (1.0–6.0; P = 0.30) days and death rate
was6.7%versus8.5%(P = 0.76).Therewere7deaths(7.9%)
of which 4 were related to severe ischemic encephalopathy
and 3 were due to intractable pulmonary haemorrhage, sep-
sis, and multiple organ failure.
The 89 neonates with severe MAS were paired to 267
controls according to GA (40.0±1.2 weeks). Gestational age
was 43 weeks in 6.7% of the neonates in this case-control
study. Mean birthweight was 3388 ± 549g in cases and
3329 ±476g in controls (P = 0.33).
Bivariate analysis identiﬁed signiﬁcant risk factors asso-
ciated to severe MAS (Table 2), that is, gestation with insuf-
ﬁcient followup; birth place in a level III facility; delivery
during day time; moderate and thick meconium; amnioin-
fusion; fetal tachycardia and fetal bradycardia; CS delivery;
low Apgar score at 1 and 5min; tracheal aspiration at birth
and pediatrician intervention at birth.
The conditional logistic regression analysis identiﬁed in-
dependent variables signiﬁcantly associated with an in-
creased risk of severe MAS: amniotic ﬂuid stained by mod-
erate or thick meconium versus thin meconium (OR = 5.63
[2.52 to 12.6; P<0.0001]); fetal tachycardia, (OR = 4.17
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Figure 2: Rates of meconium aspiration syndrome (MAS) in the
global population according to gestational age in term and post-
term deliveries.
[1.27to3.7;P = 0.019]);Apgarscore≤3at1min,(OR=87.5
[18.9 to 405; P<0.0001]); or birth in the level III facility in
comparison with birth in the level II facilities (OR = 4.8 [2.0
to 11.6; P = 0.0005]).
4. Discussion
In this epidemiological study, MSAF is a frequent event ac-
counting for 7.9% of all deliveries in non-preterm neonates.
On the other hand, MAS is a rare event (0.18%) with a need
for mechanical ventilation and/or nasal CPAP in approx-
imately one-third of them as reported in other studies [1,
2, 6]. Avoiding mechanical ventilation by using nasal CPAP
h a sp r o b a b l yam a r gi n a lr o l ea so n l y1 . 2 %o fM A Sa r etr e a t e d
withthisventilatorymode.Goldsmith[2]recentlyhighlight-
ed that the optimum modes of ventilation for MAS are not
known. He pointed out that high-frequency ventilation, in-
haled nitric oxide, surfactant and extracorporeal membrane
oxygenation are rarely required. Our series conﬁrms this
observationasonly12.0%ofMASrequiredthosetreatments.
The overall incidence of MAS and severe MAS increases
with GA as reported in recent population-based studies [8,
9]. The overall rates of MAS in the USA [8] and Burgundy
are similar: 1.0 versus 1.1 per 1000 live births (‰) at 37 WG;
1.1 versus 1.0‰ at 38WG; 1.5 versus 1.1‰ at 39WG; 2.2
versus 2.4‰ at 40WG, and 3.1 versus 2.6‰ at 41WG. Fur-
thermore the incidence of severe MAS recorded in Australia
[9] at 41 WG (0.80‰) is close to the 0.67‰ observed at 39–
41WG in our series. So, our cohort of MAS can be regarded
as representative of this pulmonary disease in the 2000s in
developed countries. It is interesting to note that the recent
population based studies [8, 9] showed a low prevalence of
MAS as compared to monocentric and multicentric studies4 International Journal of Pediatrics
Table 2: Case-control comparison in a population of neonates with GA ≥37 weeks and born through MSAF. Cases are severe MAS (i.e.,
treated by mechanical ventilation and/or continuous positive airway pressure). Paired neonates without respiratory symptoms are controls.
Cases n = 89 Controls n = 267 P value
Characteristics of the mother
Age (years) 29.7 ± 5.8 28.9 ± 5.2 0.23
Nulliparity (%) 59.5 58.1 0.80
Past history of CS
a (%) 7.95 7.87 0.97
Characteristics of pregnancy
Multiple pregnancy (%) 0 1.5 0.24
Insuﬃcient followup care (%) 8.99 0.75 <0.0001
Smoking (%) 21.6 18.5 0.52
Hypertension or preeclampsia (%) 2.28 4.91 0.28
Oligohydramnios (%) 4.5 3.4 0.62
Antenatal diagnosis of IUGR
b (%) 1.12 2.64 0.40
Gestational diabetes (%) 2.28 6.0 0.16
Clinical chorioamnionitis (%) 0 0 1.0
GBS
c vaginal carriage (%) 12.9 9.4 0.35
Placenta praevia (%) 0 0 1.0
Placental abruption (%) 0 0 1.0
Characteristics of delivery
Cord abnormalities 23.6 26.7 0.53
PROM
d (>12hr) 4.6 9.7 0.13
Antenatal steroid therapy 2.2 0 0.25
Birth place:
Level I (%) 16.8 11.2
Level II (%) 49.5 77.
Level III (%) 33.7 11.2 <0.0001
Day time delivery (%) 56.2 42.6 0.02
Induction of labor (%) 27.0 28.1 0.83
Meconium in amniotic ﬂuid
<0.0001 Thin (%) 33.7 76.4
Moderate (%) 55.1 22.8
Thick (%) 11.2 0.78
Amnioinfusion (%) 7.9 1.9 0.0067
Fetal Heart Rate (FHR):
Tachycardia (%) 17.2 4.5 0.0001
Bradycardia (%) 49.4 32.9 0.0057
Presentation:
Cephalic (%) 95.5 97.4
Breech (%) 3.4 1.9 0.37
Other (%) 1.1 0.7
Anesthesia
(i) Spinal (%) 14.6 9.4
(ii) Epidural (%) 69.7 67.0
(iii) General (%) 2.2 3.0 0.29
(iv) No anesthesia (%) 13.5 20.6
Mode of Delivery
CS (%) 37.2 20.2
Vaginal with manoeuvres (%) 17.9 17.9
Vaginal without manoeuvres (%) 44.9 61.9 0.004
Obstetrical aspiration (%) 5.6 3
Characteristics of neonates
Sex ratio (% male) 47.2 48.3 0.85
Mean birthweight (g) (±SD) 3388 (±549) 3329 (±476) 0.33International Journal of Pediatrics 5
Table 2: Continued.
Cases n = 89 Controls n = 267 P value
BW
e <10th perc. (%) 19.1 13.8
BW ≥10th perc. ≤ 90th perc. (%) 67.4 77.6
BW >90th perc. (%) 13.5 8.6 0.15
Apgar at 1min ≤3 (%) 51.7 1.1 <0.0001
Apgar at 5min ≤5 (%) 32.5 0.0 <0.0001
Tracheal aspiration at birth (%) 80.9 8.2 <0.0001
First care:
<0.0001 Pediatrician (%) 73.4 28.5
Midwife (%) 23.6 71.5
aCS: Cesarean section, bIUGR: Intrauterine growth restriction, cGBS: Group B Streptococcus, dPROM: prolonged rupture of membranes (>12 hours), eBW:
birth weight.
usually conducted in level III facilities. Our series conﬁrms
thebiasthatcouldbeinducedbynonepidemiologicalstudies
of MAS incidence as it shows that birth in a level III facility
is an independent risk factor of severe MAS. It can be spec-
ulated that regionalization of perinatal care concentrates
high risk pregnancies in level III facilities and increases the
risk for MAS. Finally, the case-control study suggested that
the care in the Burgundy population with MSAF was char-
acterized by low rates of amnioinfusion, obstetrical naso-
oropharyngeal aspiration and tracheal aspiration in infants
born with MSAF but without MAS. This ﬁts well with cur-
rent recommendations [30] about management of infants
born through MSAF: oronasopharyngeal suctioning before
thedeliveryoftheshouldersininfantsbornthroughMSAFis
useless in the prevention of MAS; tracheal suctioning should
beselectivelyappliedtononvigorousneonatesborninMSAF
according to the pivotal study of Wiswell et al. [31].
In this study the incidence of MAS is stable from 37 to
39WG and increases afterwards particularly in infants born
at 42-43WG: the risk of MAS is approximately 4-fold and
27-fold at 42WG and 43WG in comparison to 37WG.
However,theincidenceofMASinneonatesbornthrough
MSAF does not vary signiﬁcantly with GA. Similarly, pop-
ulation-based studies as well as nonpopulation-based studies
showedthatprolongedpregnancy(≥42weeks)increasesper-
inatal morbidity and mortality and greatly favours MSAF
and MAS [7, 30, 32].
Somestudiessuggestedthatpreventionofposttermpreg-
nancy prevents severe MAS [33]. The earlier induction of
labour (e.g., by 41 weeks) may prove to be beneﬁcial for the
prevention of the MAS as shown by Ross [34]. A recent Co-
chrane review [26] shows that a policy of labour induction
is associated with a reduced incidence of MAS at both 41
completed WG (relative risk (RR) = 0.29 [0.12 to 0.68]) and
42 completed WG (RR = 0.66 [0.24 to 1.81]). However, a
new randomised clinical trial [35] does not found any signif-
icant diﬀerences between induced and monitored postterm
neonates regarding neonatal morbidity. New prospective
randomised studies are required to establish whether labour
induction reduces MAS incidence without promoting other
respiratory diseases such as transient tachypnea of the new-
born (TTN) or respiratory distress syndrome (RDS).
The low incidence of severe MAS and the preeminent
role of GA on this incidence justiﬁed a case-control study
[36] paired on GA. Amniotic ﬂuid stained by moderately or
markedlythickmeconium,fetaltachycardia,andApgarscore
≤3at1minpromotesevereMAS.Thickmeconiumisusually
regarded as a common ﬁnding in severe meconium aspira-
tion syndrome [3, 6, 19, 37], and most studies were focused
on neonates born through moderate or thick MSAF. How-
ever, a lack of correlation between the severity of MAS and
the thickness of meconium has been previously suggested by
Ghidini and Spong [25] and Suresh and Sarkar [38]. Our
series conﬁrms this hypothesis as thick meconium is found
in only 11% of severe MAS (1% of controls) while moderate
and thin meconium concern 55% and 34% of severe MAS,
respectively. Apgar score ≤3 at 1min is the main risk factor
astherelativeriskis87.LowApgarscorehasbeenuniversally
associated with MAS [1, 3, 6, 9, 11–16, 28, 32, 39, 40], and
the role of fetal hypoxia has also been ascertained by elevated
cord blood concentrations of erythropoietin in both MSAF
[41]a n dM A S[ 32, 42].
It is well known that poor antenatal conditions are pre-
dominant in determining MAS. This point of view is rein-
forced as fetal tachycardia is another independent risk factor
of severe MAS in this study. This observation has been made
in many other studies, not reassuring fetal heart rate mon-
itoring being widely associated with MAS [1, 11–16, 18,
43, 44]. However, contradicting data were obtained by
Mitchell et al. [45] who concluded that FHR tracings are rel-
atively poor predictors of the presence of fetal acidosis when
amniotic ﬂuid is meconium stained.
These overall results suggest that severe MAS is an ante-
natal disease thus justifying adapted antenatal care. Nowa-
days, identiﬁcation of perinatal asphyxia remains a major
endpoint of MAS prevention [33]. Guidelines of earlier fetal
monitoring (e.g., by 40 WG) proved to be beneﬁcial for the
prevention of MAS [34].
Finally, our series failed to identify risk factors reported
in some other studies, that is, nulliparity [32, 37], male gen-
der [3], previous Cesarean section [16], and oligohydram-
nios [3]. Although our work is a population-based study
in an entire French region with 1.8 millions inhabitants,
there are only 89 cases of severe MAS over an 8-year period.
A low sample size may have favored the low number of fa-
ctors signiﬁcantly associated with severe MAS.6 International Journal of Pediatrics
5. Conclusion
Our series conﬁrms the high prevalence of MSAF after
37WG but also shows the low incidence of both MAS and
severeMASinaperiodcorrespondingtotheimplementation
of the new international recommendations on the manage-
ment of neonates born in MSAF [30].
The main risk factor of MSAF is GA but the incidence of
MASinneonatesborninMSAFdoesnotdependonGA.Our
series indicates that moderate or thick amniotic ﬂuid and
fetal tachycardia may help to anticipate the need for neonatal
resuscitation in delivery room whatever is GA. Further stud-
ies comparing perinatal factors associated with severe and
nonsevere MAS could be useful to help clinicians in delivery
room to anticipate severe MAS, a rare event which remains
life threatening.
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